Joyce F. Liu, MD, MPH

Joyce F. Liu, MD, MPH, discusses the role of Wee1 in cell cycle regulation and the rationale for targeting this protein in ovarian cancer.

Joyce F. Liu, MD, MPH, discusses the results of cediranib in combination with olaparib in a phase 3 trial in patients with recurrent platinum-sensitive ovarian cancer.

Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.

Joyce F. Liu, MD, MPH, assistant professor of medicine, Harvard Medical School, and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of PARP inhibitors in patients with recurrent ovarian cancer.

Joyce F. Liu, MD, MPH, assistant professor of medicine and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of bevacizumab (Avastin) in the treatment of patients with newly diagnosed advanced ovarian cancer.